Management of Crohn’s disease in poor responders to adalimumab

@inproceedings{Boer2014ManagementOC,
  title={Management of Crohn’s disease in poor responders to adalimumab},
  author={Nanne K. H. de Boer and Mark L{\"o}wenberg and Frank Hoentjen},
  booktitle={Clinical and experimental gastroenterology},
  year={2014}
}
Anti-tumor necrosis factor therapy with adalimumab is an effective therapy for the induction and maintenance of remission in moderate to severe Crohn's disease. Although a large proportion of patients show a favorable clinical response to adalimumab, therapy failure is common. In this review, we provide a practical overview of adalimumab therapy in patients with Crohn's disease, with a specific focus on the clinical management of adalimumab failure. In the case of inadequate efficacy, a… CONTINUE READING
3 Citations
51 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 51 references

Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease

  • W Afif, EV JrLoftus, WA Faubion
  • Am J Gastroenterol
  • 2010
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…